Hypertensive heart failure

Indian Heart Journal

Volumn 55, Issue 1, 2003, Pages 21-26

  Ramakrishnan, S ^a   Kothari, S S ^a   Bahl, V K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; GADOLINIUM PENTETATE; HYDRALAZINE; LOSARTAN; PROCOLLAGEN C PROTEINASE; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTRAST ENHANCEMENT; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DIASTOLIC BLOOD PRESSURE; EDITORIAL; EPIDEMIOLOGICAL DATA; EXERCISE TEST; GENE THERAPY; GENETIC POLYMORPHISM; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE REVASCULARIZATION; HEART PRELOAD; HEART VENTRICLE REMODELING; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; LUNG EDEMA; MEAN ARTERIAL PRESSURE; META ANALYSIS; NON INVASIVE MEASUREMENT; PATHOGENESIS; PATHOPHYSIOLOGY; POPULATION RESEARCH; QT INTERVAL; RISK ASSESSMENT; SURVIVAL;

CARDIAC OUTPUT, LOW; COMORBIDITY; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RISK ASSESSMENT; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0037617753     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (56)

1. Gillum RF. Epidemiology of heart failure in the United States. Am Heart J 1993; 126: 1042-1047
2. Mckee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med 1971; 285: 1441-1446
3. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562
4. Andersson B, Waagstein F. Spectrum and outcome of congestive heart failure in a hospitalized population. Am Heart J 1993; 126: 632-640
5. Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am Heart J 1991; 121: 1852-1853
6. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men - morbidity, risk factors and prognosis. J Intern Med 2001; 249: 253-261
7. Fox KF, Cowie MR, Wood DA, Coats AJS, Gibbs JS, Underwood SR, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 2001: 22: 228-236
8. Richards AM, Nicholls MG, Troughton RW, Lainchbury JG, Elliott J, Frampton C, et al. Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol 2002; 39: 1182-1188
9. Verdecchia P. [Cardiac failure in hypertensive cardiopathy] [Article in Italian]. Ital Heart J 2000; 1 (Suppl): 72-77
10. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-419
11. Losito A, Fagugli RM, Zampi I, Parente B, de Rango P, Giordano G, et al. Comparison of target organ damage in renovascular and essential hypertension, Am J Hypertens 1996; 9: 1062-1067
12. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am J Cardiol 1971; 27: 335-346
13. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 2000; 36: 130-138
14. Agabiti-Rosei E, Muiesan ML. Left ventricular hypertrophy and heart failure in women. J Hypertens 2002: 20 (Suppl): 834-838
15. Thakur V, Richards R, Reisin E. Obesity, hypertension, and the heart. Am J Med Sci 2001; 321: 242-248
16. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen IC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988: 108: 7-13
17. Frohlich ED. Fibrosis and ischemia: the real risks in hypertensive heart disease. Am J Hypertens 2001: 14: 194S-199S
18. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Wachtell K, Papademetriou V, et al. Relation of QT interval and QT dispersion to echocardiographic left ventricular hyper trophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. J Hypertens 2001; 19: 1883-1891
19. Ganau A, Devereux RB, Pickering TG, Roman MJ, Schnall PL, Santucci S, et al. Relation of left ventricular hemodynamic load and contractile performance of left ventricular mass in hypertension. Circulation 1990; 81: 25-36
20. Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation 1994: 90: 179-185
21. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure - a clinical mechanistic overview. Arch Intern Med 1996; 156: 1789-1796
22. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352
23. Morgan HE, Baker KM. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation 1991; 83: 13-25
24. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-228
25. Weber KT. Cardioreparation in hypertensive heart disease. Hypertension 2001; 38: 588-591
26. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865
27. Vinereanu D, Florescu N, Sculthorpe N, Tweddel AC, Stephens MR, Fraser AG. Differentiation between pathologic and physiologic left ventricular hypertrophy by tissue Doppler assessment of long-axis function in patients with hypertrophic cardiomyopathy of systemic hypertension and in athletes. Am J Cardiol 2001; 88: 53-58
28. Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38: 1222-1226
29. Wilson JM, Villareal RP, Hariharan R, Massumi A. Muthupillai R, Flamm SD. Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. Tex Heart Inst J 2002; 29: 176-180
30. Pons-Llado G, Ballester M, Borras X, Carreras F, Carrio I, Lopez-Contreras J, et al. Myocardial cell damage in human hypertension. J Am Coll Cardiol 2000; 36: 2198-2203
31. González A. López B, Ravassa S, Querejeta R, Larman M, Diez J, et al. Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension 2002; 39: 75-80
32. Fortuño MA, Ravassa S, Fortuño A, Zalba G, Diez J. Cardiomyocyte apoptotic cell death in arterial hypertension: mechanisms and potential management. Hypertension 2001; 38: 1406-1412
33. Phillips RA, Goldman ME, Ardeljan M, Arora R, Eison HB, Yu BY, et al. Determinants of abnormal left ventricular filling in early hypertension. J Am Coll Cardiol 1989; 14: 979-985
34. Ren IF. Pancholy SB, Iskandrian AS, Lighty GW Jr, Mallavarapu C, Segal BL. Doppler echocardiagraphic evaluation of the spectrum of left ventricular diastolic dysfunction in essential hypertension. Am Heart J 1994; 127: 906-913
35. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565-1574
36. Fagard R, Pardaens K. Left ventricular diastolic function predicts outcome in uncomplicated hypertension. Am J Hypertens 2001; 14: 504-508
37. Frohlich ED, Tarazi RC, Dustan HP. Clinical-physiological correlations in the development of hypertensive heart disease. Circulation 1971; 44: 446-455
38. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, et al. Assessment of left ventricular function by midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 1994; 23: 1444-1451
39. Cuocolo A, Sax FL, Brush JE, Maron BJ, Bacharach SL, Bonow RO. Left ventricular hypertrophy and impaired diastolic filling in essential hypertension. Diastolic mechanisms for systolic dysfunction during exercise. Circulation 1990; 81: 978-986
40. Gandhi SK, Powers IC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344: 17-22
41. Vasan RS, Benjamin EI. Diastolic heart failure - no time to relax. N Engl J Med 2001; 344: 56-59
42. Shah PM, Pai RG. Diastolic heart failure. Curr Probl Cardiol 1992; 17: 781-868
43. Kramer K, Kirkman P, Kitzman D, Little WC. Flash pulmonary edema: association with hypertension and re-ocurrence despite coronary revascularization. Am Heart J 2000; 140: 451-455
44. Tavazzi L. Towards a more precise definition of heart failure aetiology. Eur Heart J 2001; 22: 192-195
45. Iriarte M, Murga N, Sagastagoitia D, Molinero E, Morillas M, Salcedo A, et al. Congestive heart failure from left ventricular diastolic dysfunction in systemic hypertension. Am J Cardiol 1993; 71: 308-312
46. Di Bello V, Giorgi D, Talini E, Dell' Omo G, Palagi C, Romano MF, et al. Incremental value of ultrasonic tissue characterization (backscatter) in the evaluation of left ventricular myocardial structure and mechanics in essential arterial hypertension. Circulation 2003; 107: 74-80
47. Vasan RS, Larson MG, Benjamin EI, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33: 1948-1955
48. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202: 1028-1034
49. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 115 mm Hg. JAMA 1970; 213: 1143-1152
50. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3250-3264
51. Moser M, Hebert PR. Prevention of disease progression. left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1214-1218
52. Neal B, MacMohan S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955-1964
53. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997
54. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592
55. MacNeill BD, Hayase M, Hajjar RJ. Targeting signaling pathways in heart failure by gene transfer. Curr Atheroscler Rep 2003; 5: 178-185
56. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393